Relationship between MDM2 and P53 alterations in colorectal cancer and their involvement and prognostic value in the tunisian population

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 3, 2013, Pages 228-236

  Chaar, Ines ^a,b   Amara, Sameh ^a,b   Khiari, Mariem ^a,b   Ounissi, Donia ^a,b   Dhraif, Monia ^a   Ben Hamida, Abd E M ^b   Gharbi, Lassad ^a   Mzabi, Sabeh ^a,b   Bouraoui, Saadia ^a,b  

^a MONGI SLIM HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS   (Tunisia)

Author keywords

colorectal cancer; immunohistochemistry; MDM2 SNP309; p53; PCR SSCP; sequencing

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD DONOR; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUNISIA;

AGED; ANIMALS; CARCINOMA; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA;

EID: 84876984880     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31825f4e20     Document Type: Article

References (56)

1. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249-255.
2. Minjin L, Woon SH, Ok Kyoung K, et al. Prognostic value of p16INK4a and p14 ARF gene hyperméthylation in human colon cancer. Pathol Res Pract. 2006;202:415-424.
3. Jeong SY, Shin KH, Shin JH, et al. Microsatellite instability and mutations in DNA mismatch repair genes in sporadic colorectal cancers. Dis Colon Rectum. 2003;46:1069-1077.
4. Lynch HT, Lynch JF. Genetics of colonic cancer. Digestion. 1998; 59:481-492.
5. Silva J, Dominguez G, Silva JM, et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene. 2001;20:4586-4590.
6. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA. 2000;97:710-715.
7. Moema V, Fridz TZ, Wrba K, et al. p53 gene status and expression of p53, MDM2 and p21 waf 1 proteins in colorectal cancer. Virchows Arch. 2004;37:241-247.
8. Samowitz WS, Curtin KM, Edwaeds S, et al. Prognostic significance of p53 mutation in colorectal cancer at the population level. Int J Cancer. 2002;99:597-602.
9. Paluszkiewicz P, Berbeæ H, Pawlowska-Wakowicz B, et al. p53 protein accumulation in colorectal cancer tissue has prognostic value only in left sided colon tumors. Cancer Detect Prev. 2004;28:252-259.
10. Soussi T, Beroud C. Significance of p53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat. 2003;21:192-200.
11. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci. 2000;910:121-137.
12. Vishwa jet A, Yukio T, Kouki I. Methylation of p14arf gene in meningiomas and its correlation to the p53 and mutation. Mod Pathol. 2004;17:705-710.
13. Piette J, Neel H, Marechal V. MDM2: keeping p53 under control. Oncogene. 1997;15:1001-1010.
14. Ttigashyama M, Doi O, Ykokouchi H, et al. MDM2 gene amplification and expression in non-small cell lung cancer: immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 accumulation. Br J Cancer. 1997;75:1302-1308.
15. Sajjad K, Arif A. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol. 2009;11:1381-1387.
16. Hao XP, Gunther T, Roessner A, et al. Expression of MDM2 and p53 in epithelial neoplasms of the colo- rectum. Mol Pathol. 1998; 51:26-29.
17. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453-3459.
18. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119:591-602.
19. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005;65:5481-5484.
20. Bond GL, Levine AJ, et al. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26: 1317-1323.
21. Lind H, Zienolddiny S, Ekstrom PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of non small cell lung cancer. Int J Cancer. 2006;119:718-721.
22. Hong Y, Miao X, Zhang X, et al. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65:9582-9587.
23. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 2006;20: 4434-4440.
24. Ghada AF, Boris Y, Bhuvaneswari K, et al. MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma. J Gastrointest Surg. 2000;4:109-114.
25. Merup M, Juliusson G, Xu XH, et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukemia. Eur J Hematol. 1997;58:174-180.
26. Giannikaki E, Kouvidou C, Tzardi M, et al. p53 protein expression in breast carcinoma cooperative study with wild type p53 induced proteins MDM2 and p21/WAF1. Anticancer Res. 1997;17: 2123-2127.
27. Wurl P, Meye A, Schmidt H, et al. High prognostic significance of MDM2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 1998;16:1183-1185.
28. Schiebe M, Ohneseit P, Hoffmann W, et al. Analysis of MDM2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol. 2000;49:197-203.
29. Gustafsson B, Axelsson B, Christensson B, et al. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol. 2001;18:497-508.
30. Lukas J, Gao DQ, Kashmeshian M, et al. Alternative and aberrant messenger RNA splicing of the MDM2 oncogene in invasive breast cancer. Cancer Res. 2001;61:3212-3219.
31. Hori M, Shimazaki J, Inagawa S, et al. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat. 2002;71:77-83.
32. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 protein accumulation. Br J Cancer. 1997;75:1302-1308.
33. Polsky D, Bastian BC, Hazan C, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorogenesis of cutaneous melanoma. Cancer Res. 2001;61:7642-7646.
34. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002;94:1803-1806.
35. Ito K, Satoru I, Yoko Takagi KS. MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum. 2008;51: 1395-1402.
36. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262-2267.
37. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006;285-288.
38. Hiroshi H, Yuji H, Nobuyuki K, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123-4129.
39. Chaoliang X, Jun L, Lingxian Y, et al. Methylation of p14ARF and abnormal expression of p53 and MDM2 in colorectal cancer: role and correlation. Sci Res Essays. 2010;5:1669-1675.
40. Deepak R, Rehan A, Dongshu C, et al. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathways. Cancer Biol Ther. 2008;7:1959-1967.
41. Ray RM, Bhattacharya S, Johnson LR. MDM2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis. 2011;16:35-44.
42. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem. 2010;31:31-38.
43. Sameer AS, Ul Rehman S, Pandith AA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15:244-252.
44. Ligang LIU, Tiecheng PAN, Jun LI, et al. The correlation of p53 and nm23-H1 expression with invasiveness and metastasis in esophageal carcinoma. Chin Ger J Clin Oncol. 2002;4:194-198.
45. Georgee T, Eleni K, Joanna GP, et al. p53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res. 2009;29:785-792.
46. Yuan-Tzu L, Shih-Ching C, Anna Fen-Yau L, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007;22:499-506.
47. Nasif WA, Lotfy M, El-Sayed IH, et al. Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer. Med Oncol. 2007;23:237-244.
48. Fabien S, Marie-Aude Le Frere B, Rodrigo Q, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol. 2004;45:475-482.
49. Lun-Xiu Q, Zhao-You T, Zeng-Chen M, et al. p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8:459-463.
50. Garg K, Leitao MM Jr, Christine AW, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23:80-92.
51. Kim H, Yom C, Lee J, et al. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat. 2010;121:777-788.
52. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602.
53. Hav M, Libbrecht L, Ferdinande L. MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? Virchows Arch. 2011;458:197-203.
54. Schiebe M, Ohneseit P, Hoffmann W, et al. Analysis of MDM2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol. 2000;49:197-203.
55. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26: 3453-3459.
56. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends MolMed. 2007;13:23-31.